Sirtuin 1 (SIRT1) activation attenuated hepatic steatosis and inflammation in HFD-induced NAFLD by inhibiting CD38 expression and NF-κB signaling pathway 24-26. The gene discussed is CD38; the disease is metabolic dysfunction-associated steatotic liver disease.